ArticleNeuroscience bulletin2026
A Humanized Knock-in Mouse Model of the PSEN1 V97L Mutation from a Major Chinese Alzheimer's Disease Pedigree Reveals Early Neuroinflammation.
Article in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the presenilin-1 (PSEN1) gene cause familial Alzheimer's disease (FAD). The PSEN1 V97L mutation is prevalent in Chinese FAD families. Previous studies using a transgenic model that overexpresses PSEN1 V97L have substantially contributed to understanding FAD pathogenesis. However, these models have limitations, including random genetic integration of the transgene, supra-physiological protein expression levels, and retention of endogenous mouse PSEN1 genes. The genetic engineering of novel mouse models carrying human mutant PSEN1 using knock-in methods addresses many of these issues. Here, we generated a humanized PSEN1 V97L knock-in (hV97L) mouse model. At 4 months of age, hV97L mice exhibited early neuroinflammation characterized by microglial activation and M1-like polarization, without Aβ pathology. By 8 months, cognitive deficits, dendritic loss, and myelin damage emerged, still in the absence of amyloid pathology. Our findings demonstrate that the PSEN1 V97L mutation triggers neuroinflammation before cognitive onset, providing a clinically relevant model for early therapeutic targeting.
Indexed as
Identifiers
42334726What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.